Mometasone furoate nasal spray for the treatment of asthma

References

• GINA Report. Global strategy for asthma management and prevention. Available from: http://www.ginasthma.com.
   Google Scholar
• Eder W, Ege MJ, Von Mutius E. The asthma epidemic. N Engl J Med. 2006;355:2226–2235.
   PubMed Web of Science ®Google Scholar
• Asher MI, Montefort S, Björkstén B, et al. ISAAC Phase Three Study Group. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet. 2006 Aug 26;368(9537):733–743.
   PubMed Web of Science ®Google Scholar
• Krouse JH. The unified airway-conceptual framework. Otolaryngol Clin North Am. 2008;41:257–266.
   PubMed Web of Science ®Google Scholar
• Lange RJ. Comorbidities of asthma and the unified airway. Int Forum Allergy Rhinol. 2015 Sep;5(Suppl 1):S17–22.
   Google Scholar
• Fiocchi A, Fox AT. Preventing progression of allergic rhinitis: the role of specific immunotherapy. Arch Dis Child Educ Pract Ed. 2011 Jun;96(3):91–100.
   PubMed Web of Science ®Google Scholar
• Shaaban R, Zureik M, Soussan D, et al. Rhinitis and onset of asthma: a longitudinal population-based study. Lancet. 2008 Sep 20;372(9643):1049–1057.
   PubMed Web of Science ®Google Scholar
• Bousquet J, Gaugris S, Kocevar VS, et al. Increased risk of asthma attacks and emergency visits among asthma patients with allergic rhinitis: a subgroup analysis of the investigation of montelukast as a partner agent for complementary therapy [corrected]. Clin Exp Allergy. 2005 Jun;35(6):723–727.
   PubMed Web of Science ®Google Scholar
• Brozek JL, Bousquet J, Baena-Cagnani CE, et al. Allergic rhinitis and its impact on asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol. 2010 Sep;126(3):466–476.
   PubMed Web of Science ®Google Scholar
• Oka A, Matsunaga K, Kamei T, et al. Ongoing allergic rhinitis impairs asthma control by enhancing the lower airway inflammation. J Allergy Clin Immunol Pract. 2014 Mar-Apr;2(2):172–178.
   PubMed Web of Science ®Google Scholar
• Watson WT, Becker AB, Simons FE. Treatment of allergic rhinitis with intranasal corticosteroids in patients with mild asthma: effect on lower airway responsiveness. J Allergy Clin Immunol. 1993 Jan;91(1 Pt 1):97–101.
   PubMed Web of Science ®Google Scholar
• Crystal-Peters J, Neslusan C, Crown WH, et al. Treating allergic rhinitis in patients with comorbid asthma: the risk of asthma-related hospitalizations and emergency department visits. J Allergy Clin Immunol. 2002 Jan;109(1):57–62.
   PubMed Web of Science ®Google Scholar
• Pavord ID, Jeffery PK, Qiu Y, et al. Airway inflammation in patients with asthma with high-fixed or low-fixed plus as-needed budesonide/formoterol. J Allergy Clin Immunol. 2009 May;123(5):1083–1087.
   PubMed Web of Science ®Google Scholar
• Frieri M, Therattil J, Chavarria V, et al. Effect of mometasone furoate on early and late phase inflammation in patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 1998 Nov;81(5):431–437.
   PubMed Web of Science ®Google Scholar
• Yang D, Wang J, Bunjhoo H, et al. Comparison of the efficacy and safety of mometasone furoate to other inhaled steroids for asthma: a meta-analysis. Asian Pac J Allergy Immunol. 2013 Mar;31(1):26–35.
   PubMed Web of Science ®Google Scholar
• Stanbury RM, Graham EM. Systemic corticosteroid therapy--side effects and their management. Br J Ophthalmol. 1998;82(6):704–708.
   PubMed Web of Science ®Google Scholar
• Kelly HW, Nelson HS. Potential adverse effects of the inhaled corticosteroids. J Allergy Clin Immunol. 2003;112(3):469–478. quiz479
   PubMed Web of Science ®Google Scholar
• Nathan RA, Yancey SW, Waitkus-Edwards K, et al. Fluticasone propionate nasal spray is superior to montelukast for allergic rhinitis while neither affects overall asthma control. Chest. 2005 Oct;128(4):1910–1920.
   PubMed Web of Science ®Google Scholar
• Lange B, Lukat KF, Rettig K, et al. Efficacy, cost-effectiveness, and tolerability of mometasone furoate, levocabastine, and disodium cromoglycate nasal sprays in the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2005 Sep;95(3):272–282.
   PubMed Web of Science ®Google Scholar
• Penagos M, Compalati E, Tarantini F, et al. Efficacy of mometasone furoate nasal spray in the treatment of allergic rhinitis. Meta-analysis of randomized, double-blind, placebo-controlled, clinical trials. Allergy. 2008 Oct;63(10):1280–1291.
   PubMed Web of Science ®Google Scholar
• Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/020762_S007_NASONEX_AQUEOUS_NASAL_SPRAY.pdf.
   Google Scholar
• Cave A, Arlett P, Lee E. Inhaled and nasal corticosteroids: factors affecting the risks of systemic adverse effects. Pharmacol Ther. 1999;83(3):153–179.
   PubMed Web of Science ®Google Scholar
• Hochhaus G. Pharmacokinetic/pharmacodynamic profile of mometasone furoate nasal spray: potential effects on clinical safety and efficacy. Clin Ther. 2008 Jan;30(1):1–13.
   PubMed Web of Science ®Google Scholar
• Foresi A, Pelucchi A, Gherson G, et al. Once daily intranasal fluticasone propionate (200 micrograms) reduces nasal symptoms and inflammation but also attenuates the increase in bronchial responsiveness during the pollen season in allergic rhinitis. J Allergy Clin Immunol. 1996;98:274–282.
   PubMed Web of Science ®Google Scholar
• Barnes J, Adcock IM. How do corticosteroids work in asthma? Ann Intern Med. 2003;139(5 Pt 1):359–370.
   PubMed Web of Science ®Google Scholar
• Valotis A, Neukam K, Elert O, et al. Human receptor kinetics, tissue binding affinity, and stability of mometasone furoate. J Pharm Sci. 2004;93(5):1337–1350.
   PubMed Web of Science ®Google Scholar
• Smith CL, Kreutner W. In vitro glucocorticoid receptor binding and transcriptional activation by topically active glucocorticoids. Arzneimittelforschung. 1998;48:956–960.
   PubMed Web of Science ®Google Scholar
• Derendrof H, Nave H, Drollmann A, et al. Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. Eur Respir J. 2006;28(5):1337–1350.
   Google Scholar
• Sastre J, Mosges R. Local and systemic safety of intranasal corticosteroids. J Investig Allergol Clin Immunol. 2012;22(1):1–12.
   PubMed Web of Science ®Google Scholar
• Teng XW, Cutler DJ, Davies NM. Mometasone furoate degradation and metabolism in human biological fluids and tissues. Biopharm Drug Dispos. 2003 Nov;24(8):321–333.
   PubMed Web of Science ®Google Scholar
• Zbaida S, Shannon D, Du Y, et al. In vitro metabolism of mometasone furoate. Faseb J. 1997;11(8 Suppl S):A829.
   Google Scholar
• Yamada T, Yamamoto H, Kubo S, et al. Efficacy of mometasone furoate nasal spray for nasal symptoms, quality of life, rhinitis-disturbed sleep, and nasal nitric oxide in patients with perennial allergic rhinitis. Allergy Asthma Proc. 2012 Mar-Apr;33(2):e9–16.
   PubMed Web of Science ®Google Scholar
• Pitsios C, Papadopoulos D, Kompoti E, et al. Efficacy and safety of mometasone furoate vs nedocromil sodium as prophylactic treatment for moderate/severe seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2006 May;96(5):673–678.
   PubMed Web of Science ®Google Scholar
• Kuna P, Wasiak W, Jones S, et al. Comparative safety and efficacy of two formulations of mometasone nasal spray in adult seasonal allergic rhinitis. Allergy Asthma Proc. 2014 Jul-Aug;35(4):332–337.
   PubMed Web of Science ®Google Scholar
• Meltzer EO, Baena-Cagnani CE, Gates D, et al. Relieving nasal congestion in children with seasonal and perennial allergic rhinitis: efficacy and safety studies of mometasone furoate nasal spray. World Allergy Organ J. 2013 Mar 4;6(1):5.
   PubMedGoogle Scholar
• Herman H. Once-daily administration of intranasal corticosteroids for allergic rhinitis: a comparative review of efficacy, safety, patient preference, and cost. Am J Rhinol. 2007 Jan-Feb;21(1):70–79.
   PubMedGoogle Scholar
• Meltzer EO, Bardelas J, Goldsobel A, et al. A preference evaluation study comparing the sensory attributes of mometasone furoate and fluticasone propionate nasal sprays by patients with allergic rhinitis. Treat Respir Med. 2005;4(4):289–296.
   PubMedGoogle Scholar
• Taramarcaz P, Gibson PG. Intranasal corticosteroids for asthma control in people with coexisting asthma and rhinitis. Cochrane Database Syst Rev. 2003;4:Art. No.CD003570.
   Google Scholar
• Baiardini I, Villa E, Rogkakou A, et al. Effects of mometasone furoate on the quality of life: a randomized placebo-controlled trial in persistent allergic rhinitis and intermittent asthma using the Rhinasthma questionnaire. Clin Exp Allergy. 2011 Mar;41(3):417–423.
   PubMed Web of Science ®Google Scholar
• Gani F, Pozzi E, Crivellaro MA, et al. The role of patient training in the management of seasonal rhinitis and asthma: clinical implications. Allergy. 2001 Jan;56(1):65–68.
   PubMed Web of Science ®Google Scholar
• Pedroletti C, Lundahl J, Alving K, et al. Effect of nasal steroid treatment on airway inflammation determined by exhaled nitric oxide in allergic schoolchildren with perennial rhinitis and asthma. Pediatr Allergy Immunol. 2008 May;19(3):219–226.
   PubMed Web of Science ®Google Scholar
• American Lung Association–Asthma Clinical Research Centers’ Writing Committee, Dixon AE, Castro M, Cohen RI, et al. Efficacy of nasal mometasone for the treatment of chronic sinonasal disease in patients with inadequately controlled asthma. J Allergy Clin Immunol. 2015 Mar; 135(3):701–709.e5.
   PubMed Web of Science ®Google Scholar
• Yatera K, Yamasaki K, Noguchi S, et al. Prevalence of sinusitis and efficacy of intranasal corticosteroid treatment on asthmatic symptoms in asthmatic patients with rhinosinusitis: a pilot study. Int Forum Allergy Rhinol. 2015 Dec 1. doi:10.1002/alr.21672. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Corren J, Adinoff AD, Buchmeier AD, et al. Nasal beclomethasone prevents the seasonal increase in bronchial responsiveness in patients with allergic rhinitis and asthma. J Allergy Clin Immunol. 1992 Aug;90(2):250–256.
   PubMed Web of Science ®Google Scholar